Product Description
Oliceridine is a novel selective µ-receptor G-protein pathway modulator. It has the property of activating G-protein signaling while causing low beta-arrestin recruitment to the µ-receptor. Intravenous oliceridine showed statistically superior analgesia than placebo in patients with moderate or severe pain after surgery, with a favorable safety and tolerability profile regarding respiratory and gastrointestinal adverse effects, compared with morphine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33423508/)
Mechanisms of Action: OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: Acute Pain | Pain Unspecified | Substance Abuse Unspecified
Known Adverse Events: Dizziness | Headache | Pruritus | Constipation | Hypoxia
Company: Trevena
Company Location: CHESTERBROOK PA 19087
Company CEO: Carrie L. Bourdow
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Acute Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-006334-39 | P2 |
Completed |
Acute Pain |
2022-06-10 |